Diagnostics company SphingoTec GmbH and 4TEEN4 Pharmaceuticals GmbH announced today the publication of new data showing that high blood levels of Dipeptidyl Peptidase 3 (DPP3) are indicating upcoming multiple organ failure and mortality risk in burn patients.
Diagnostics company SphingoTec GmbH and 4TEEN4 Pharmaceuticals GmbH announced today the publication of new data showing that high blood levels of Dipeptidyl Peptidase 3 (DPP3) are indicating upcoming multiple organ failure and mortality risk in burn patients.
4TEEN4 Pharmaceuticals GmbH today for the first time reported preclinical data on its lead product Procizumab, a therapeutic antibody targeting circulating Dipeptidyl Peptidase 3 (DPP3) for the treatment of patients with acute myocardial depression including acute heart failure and cardiogenic shock.